JAK-1 Inhibitor, ABT-494, Seen to Aid RA Patients Now Advancing into Phase 3 Tests
News
Recent results from a Phase 2b clinical trial evaluating the JAK-1 inhibitor, ABT-494, in patients with moderate to severe rheumatoid arthritis (RA) who did not respond to methotrexate (MTX) therapy show that, ... Read more